VIDEOS FROM EXPERTS

HEAR FROM YOUR PEERS AND THEIR PATIENTS

Aanika, TEZSPIRE patient.

Aanika, TEZSPIRE patient.

SEE WHAT EXPERTS and patients HAVE TO SAY ABOUT TEZSPIRE

10 Things to Know About TEZSPIRE

Follow along with your peers as they explore 10 Things to Know About TEZSPIRE® (tezepelumab-ekko). This video details the mechanism of action, study design of 2 pivotal trials, along with the efficacy and safety data.

Speaker Series On Demand with Dr Amy Wagelie-Steffen

Follow along with Dr Amy Wagelie-Steffen as she discusses the 2 pivotal trials for TEZSPIRE® (tezepelumab-ekko). Consider what the mechanism of action, study designs, efficacy and safety data may mean for your patients.

TEZspirational Stories with Monique & Dr Ben Close

Join this real patient-HCP discussion between Monique and allergist Dr Ben Close, as they explore Monique's journey with severe asthma and adding TEZSPIRE® (tezepelumab-ekko) to her treatment plan. Follow along this first-hand patient experience to consider what this conversation may mean for your patients.

TEZSPIRE Program Highlights

Join allergist/immunologist Dr Tina Abraham as she dives into the 2 pivotal trials for TEZSPIRE® (tezepelumab-ekko). Follow along as she discusses the mechanism of action, key biomarkers, and what this may mean for patients.

My TEZSPIRE Moment with Dr Warner Carr

Join practicing allergist Dr Warner Carr of Irvine, CA, Chair of Advocacy for the American College of Asthma, Allergy & Immunology as he discusses his experience prescribing TEZSPIRE® (tezepelumab-ekko). Follow along as he talks about evaluating patients with severe asthma, optimizing for better asthma control, and discusses how TEZSPIRE can fit within the treatment journey.

My TEZSPIRE Moment with Dr Regan Pyle

Join allergist & immunologist Dr Regan Pyle of Avon, CO to hear why she chose to prescribe TEZSPIRE® (tezepelumab-ekko) to Zach, a 13-year old patient with severe asthma. Follow along as she discusses this patient case.

My TEZSPIRE Moment with Dr Shahzad Mustafa

Join allergist Dr Shahzad Mustafa of Rochester, NY as he discusses a 40-year-old patient with severe asthma, Yara. Yara has experienced multiple exacerbations and symptoms requiring emergency department and hospital visits despite adherence to her treatment plan. Find out why Dr Mustafa added TEZSPIRE® (tezepelumab-ekko) to Yara's treatment plan.

My TEZSPIRE Moment with Dr Nicole Chase

Hear why St. Paul, MN-based allergist Dr Nicole Chase chose to prescribe TEZSPIRE® (tezepelumab-ekko) to Althea, a 65-year-old who frequently experienced exacerbations despite being adherent to her treatment regimen.

My TEZSPIRE Moment with Dr Autumn Burnette

Join Washington DC-based allergist Dr Autumn Burnette as she discusses her experience prescribing TEZSPIRE® (tezepelumab-ekko). Hear why she thought TEZSPIRE was right for Kristen, an active 35-year-old with severe asthma who came down with a respiratory infection, which exacerbated her asthma symptoms.

My TEZSPIRE Moment with Dr Matt Williams

Join pulmonologist Dr Matt Williams of Annandale, VA to hear why he chose TEZSPIRE® (tezepelumab-ekko) for 3 challenging patients with severe asthma who had complex phenotypes that ranged from allergic, eosinophilic to type 2 independent asthma.

Speaker Series On Demand with Dr Geoffrey Chupp

Watch to learn about TEZSPIRE® (tezepelumab-ekko) with Dr Geoffrey Chupp in this on-demand speaker program series.

Speaker Series On Demand with Dr Priya Bansal

Watch and follow along with Dr Priya Bansal to learn about TEZSPIRE® (tezepelumab-ekko) in this on-demand speaker program series.

Clinical Implications of Uncontrolled Inflammation in Severe Asthma with Dr Michael Marcus

Join Dr Michael Marcus as he explains the role of thymic stromal lymphopoietin (TSLP) in severe asthma and examines the efficacy and safety profile of TEZSPIRE® (tezepelumab-ekko). The mechanism of action is not fully understood. Follow along to learn more.

Understanding TEZSPIRE with Drs Rohit Katial and Nicole Chase

Shadow Drs Rohit Katial and Nicole Chase as they uncover various aspects of severe asthma and take a closer look at the allergic and eosinophilic patient types. They’ll also explore the relationship between TSLP and mucus plugs, and the efficacy and safety profile of TEZSPIRE® (tezepelumab-ekko).

10 Things to Know About TEZSPIRE Video Thumbnail

10 Things to Know About TEZSPIRE

Mechanism of Action of TEZSPIRE Video Thumbnail

The Mechanism of Action of TEZSPIRE

Speaker Series with Dr. Amy Wagelie-Steffen Video Thumbnail

Speaker Series On Demand with Dr Amy Wagelie-Steffen

TEZspirational Stories with Monique & Dr. Ben Video Thumbnail

TEZspirational Stories with Monique & Dr Ben Close

TEZSPIRE Program Highlights Video Thumbnail

TEZSPIRE Program Highlights

TEZSPIRE Moment feat. Dr. Warner Carr Video Thumbnail

My TEZSPIRE Moment with Dr Warner Carr

TEZSPIRE Moment feat. Dr. Regan Pyle Video Thumbnail

My TEZSPIRE Moment with Dr Regan Pyle

TEZSPIRE Moment feat. Dr. Shahzad Mustafa Video Thumbnail

My TEZSPIRE Moment with Dr Shahzad Mustafa

TEZSPIRE Moment feat. Dr. Nicole Chase Video Thumbnail

My TEZSPIRE Moment with Dr Nicole Chase

TEZSPIRE Moment feat. Dr. Autumn Burnette Video Thumbnail

My TEZSPIRE Moment with Dr Autumn Burnette

TEZSPIRE Moment feat. Dr. Matt Williams Video Thumbnail

My TEZSPIRE Moment with Dr Matt Williams

Speaker Series with Dr. Geoffrey Chupp Video Thumbnail

Speaker Series On Demand with Dr Geoffrey Chupp

Speaker Series with Dr. Priya Bansal Video Thumbnail

Speaker Series On Demand with Dr Priya Bansal

Clinical Implications of Uncontrolled Inflammation Video Thumbnail

Clinical Implications of Uncontrolled Inflammation in Severe Asthma with Dr Michael Marcus

Understanding TEZSPIRE Video Thumbnail

Understanding TEZSPIRE with Drs Rohit Katial and Nicole Chase

Filter by:
Filter by:

     

    Loading...

.Request a Rep to Learn More

DO YOU HAVE PATIENTS TREATED WITH TEZSPIRE?

ASK THEM TO SHARE THEIR TEZSPIRE STORY 

CRSwNP=chronic rhinosinusitis with nasal polyps.

 

Back

Help Get Your Patients Started

Next

Request a Rep and/or an FRM

Important Safety Information

Collapse

CONTRAINDICATIONS

Known hypersensitivity to tezepelumab-ekko or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

Acute Asthma Symptoms or Deteriorating Disease

TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.

Abrupt Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Live Attenuated Vaccines

The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 3%) are:

  • Asthma: pharyngitis, arthralgia, and back pain.
  • Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory tract infection, epistaxis, pharyngitis, back pain, influenza, injection site reaction and arthralgia

USE IN SPECIFIC POPULATIONS

There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

INDICATION

TEZSPIRE is indicated for:

  • the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus
  • the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)

Please see full Prescribing Information, including
Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products Opens new window. Opens new window

Important Safety Information

 +

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2.  Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19)(suppl):1-60.

Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Data on File. US-105253, AstraZeneca Pharmaceuticals LP. 7. Data on File. US-98796, AstraZeneca Pharmaceuticals LP.

Reference: 1. Data on File. US-105253, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 3. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 4. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.

Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025.

References: 1. Price D, Dale P, Elder E, Chapman KR. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries. J Asthma. 2014;51(2):127-135. 2. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 3. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 4. Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. 5. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 7. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 8. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236.

References: 1. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 5. Laidlaw TM, Menzies-Gow A, Caveney S, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915-932. 6. Data on File. REF-263922, AstraZeneca Pharmaceuticals LP. 7. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 7. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 8. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997-1009. 9. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 10. Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):1-10. 11. Data on File. REF-176078, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-188753, AstraZeneca Pharmaceuticals LP. 13. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP.

References: 1. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 5. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 6. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 7. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 8. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 10. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 11. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Corren J, Parnes JR, Wang L, et al. Appendix to: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(suppl):1-54. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60. 6. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 7. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 3. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 7. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 8. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP. 9. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 10. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 11. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 12. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 13. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 14. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11. 15. Data on File. US-98281, AstraZeneca Pharmaceuticals LP.

References: 1. Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 5. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 6. Brace yourselves: the biggest week for asthma attacks is coming. Asthma and Allergy Foundation of America. Published August 25, 2022. Accessed August 5, 2025. https://community.aafa.org/blog/September-Asthma-Peak-brace-yourselves-the-biggest-week-for-asthma-attacks-is-coming. 7. Protect your child against the September epidemic. National Jewish Health. Accessed August 5, 2025. https://www.nationaljewish.org/conditions/health-information/multimedia/living-with-asthma/protect-your-child-against-the-september-epidemic. 8. Sheehan WJ, Patel SJ, Margolis RH, et al. Pediatric asthma exacerbations during the COVID-19 pandemic: absence of the typical fall seasonal spike in Washington, DC. J Allergy Clin Immunol Pract. 2021;9(5):2073-2076. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 10. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5.

References: 1. van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy. 2017;72(2):282-290. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Data on File. US-98796, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-292218, AstraZeneca Pharmaceuticals LP. 3. Pfaar O, Han JK, Desrosiers M, et al. Onset of action of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in the phase 3 WAYPOINT study. Presented at: European Rhinologic Society (ERS) 2025 Congress; June 22-25, 2025; Budapest, Hungary. 4. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps [Appendix]. N Engl J Med. 2025;392(12):1178-1188. 5. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025;392(12):1178-1188. 6. Chowdhury NI, Mace JC, Bodner TE, et al. Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(12):1149-1155. 7. Data on File. REF-287771, AstraZeneca Pharmaceuticals LP. 8. Data on File. WAYPOINT Clinical study report. Tezepelumab D5242C00001; January 23, 2025.

References: 1. Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149(5):1491-1503. 2. Peters A, Zhao X, Near AM, et al. Real-world outcomes following biologic initiation in US patients with chronic rhinosinusitis with nasal polyps. Adv Ther. 2025;42(4):1783-1799. 3. Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725-739. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. Ha J-G, Cho H-J. Unraveling the role of epithelial cells in the development of chronic rhinosinusitis. Int J Mol Sci. 2023;24(18):14229. 7. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 8. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56.

This product information is intended for US Healthcare Professionals only.

TEZSPIRE is a registered trademark of Amgen Inc.
and AstraZeneca.
©2026 AstraZeneca. All rights reserved. US-106943; US-110429 Last Updated 7/26US-99228; US-106278; US-106943 Last Updated 3/26